Prevention of hepatitis A by Havrix: a review (Q36238689)

13 August 2017

1 reference

title

Prevention of hepatitis A by Havrix: a review (English)

1 reference

13 August 2017

1 reference

2

Pierre Van Damme

1 reference

13 August 2017

Koen Van Herck

1

1 reference

13 August 2017

1 August 2005

1 reference

Expert Review of Vaccines

13 August 2017

1 reference

13 August 2017

4

1 reference

13 August 2017

4

1 reference

13 August 2017

459-471

1 reference

The cost of hepatitis A infections in American adolescents and adults in 1997.

13 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Fulminant hepatitis in patients with chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Liver failure in children with hepatitis A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Clinical course and consequences of hepatitis A infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Declining hepatitis A seroprevalence: a global review and analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Hepatitis A shifting epidemiology in South-East Asia and China

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Epidemiology and prophylaxis of viral hepatitis: a global perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Antibody against hepatitis A in seven European countries. I. Comparison of prevalence data in different age groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

21 January 2018

Hepatitis A immunisation

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Vaccination of travelers against hepatitis A and B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

A survey on hepatitis A in Portuguese children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Decline in anti-HAV prevalence in the Milan area between 1958 and 1992.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Seroprevalence of viral hepatitis A in the Czech Republic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

The changing epidemiological pattern of hepatitis A in an urban population of India: emergence of a trend similar to the European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Knowledge, attitudes and practices in travel-related infectious diseases: the European airport survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Travelers' knowledge, attitudes and practices on the prevention of infectious diseases: results from a study at Johannesburg International Airport

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Travel health knowledge, attitudes and practices among Australasian travelers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Clinical development of a new inactivated hepatitis A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Safety and immunogenicity of a new formulation of an inactivated hepatitis A vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Immunogenicity and protectivity of a new liposomal hepatitis A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Hepatitis A booster vaccination: is there a need?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Production, quality control and characterization of an inactivated hepatitis A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Clinical experience with an inactivated hepatitis A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Comparative immunogenicity and tolerance of Vaqta and Havrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Comparison of immunogenicity of two hepatitis A vaccines--VAQTA and HAVRIX--in young adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Rapid antibody response after vaccination with a virosomal hepatitis a vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal®)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Excellent booster response 4-6 y after a single primary dose of an inactivated hepatitis A vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Excellent booster response 4 to 8 years after a single primary dose of an inactivated hepatitis A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Successful Booster Antibody Response up to 54 Months after Single Primary Vaccination with Virosome-Formulated, Aluminum-Free Hepatitis A Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Interference assessment of yellow fever vaccine with the immune response to a single-dose inactivated hepatitis A vaccine (1440 EL.U.). A controlled study in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Concomitant vaccination against hepatitis A and typhoid fever.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Immunogenicity of Twinrix in older adults: a critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

A breakthrough case of hepatitis A disease following a full vaccination schedule of three doses of a combined hepatitis A and B vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Immunogenicity of combined hepatitis A and B vaccine in elderly persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Six years' follow-up after hepatitis A vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Long-term immunogenicity of an inactivated virosome hepatitis A vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Effect of postexposure vaccination in a chimpanzee model of hepatitis A virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Outbreak of hepatitis A in the injecting drug user and homeless populations in Bristol: control by a targeted vaccination programme and possible parenteral transmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Use of hepatitis A vaccine in a community-wide outbreak of hepatitis A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Hepatitis A control in a refugee camp by active immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Experience of hepatitis A vaccination during an outbreak in a nursery school of Tuscany, Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Risk groups for hepatitis A virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Epidemiology and prevention of hepatitis A in travelers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Hepatitis A among homosexual men and injection drug users: more evidence for vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Hepatitis A vaccination during an outbreak among gay men in Montréal, Canada, 1995-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Hepatitis A vaccination in chronic carriers of hepatitis B virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Immunogenicity and safety of hepatitis A vaccine in children with chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Review article: hepatitis vaccination in patients with chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

HAV infection in chronic liver disease: a rationale for vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Control of hepatitis A through routine vaccination of children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Incidence of hepatitis A in the United States in the era of vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Incidence of hepatitis A in Israel following universal immunization of toddlers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Molecular characterization of hepatitis-A-virus infections, in the context of two outbreaks in southern Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

A multistate, foodborne outbreak of hepatitis A. National Hepatitis A Investigation Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Rapid protection and vaccination against hepatitis A for travellers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Immunogenicity and reactogenicity of the combined hepatitis A and B vaccine in young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Effect of Hepatitis A Vaccination Programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

Combined hepatitis A and B vaccine in elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.459

21 January 2018

Identifiers

DOI

10.1586/14760584.4.4.459

1 reference

13 August 2017

1 reference

PubMed ID

16117704